Abstract
KRAS is the most commonly mutated gene in cancer and is associated with poor prognosis. Up to 44% of gastrointestinal cancers (GI) have KRAS mutations with the highest incidence observed in pancreatic cancer. Successfully targeting a specific mutation KRAS G12C in non-small cell lung cancer (NSCLC) has challenged the dogma that KRAS is a “non-druggable” target. With the advent of several RAS inhibitors, the opportunities for targeted therapy in GI cancers appears promising. This article provides in-depth review of KRAS mutations, and recently completed and ongoing clinical trials targeting KRAS mutations in GI cancers. In addition, this article reviews potential limitations for KRAS targeting in GI cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
